Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) Invested Capital (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Invested Capital for 15 consecutive years, with $11.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital fell 13.13% year-over-year to $11.9 million, compared with a TTM value of $11.9 million through Oct 2025, down 13.13%, and an annual FY2025 reading of $11.9 million, down 13.13% over the prior year.
  • Invested Capital was $11.9 million for Q4 2025 at Pharma-Bio Serv, roughly flat from $11.9 million in the prior quarter.
  • Across five years, Invested Capital topped out at $23.8 million in Q3 2021 and bottomed at $11.9 million in Q4 2025.
  • Average Invested Capital over 5 years is $16.1 million, with a median of $16.0 million recorded in 2022.
  • The sharpest move saw Invested Capital rose 6.85% in 2021, then crashed 32.26% in 2022.
  • Year by year, Invested Capital stood at $18.9 million in 2021, then decreased by 12.46% to $16.6 million in 2022, then fell by 2.6% to $16.1 million in 2023, then fell by 14.95% to $13.7 million in 2024, then decreased by 13.13% to $11.9 million in 2025.
  • Business Quant data shows Invested Capital for PBSV at $11.9 million in Q4 2025, $11.9 million in Q3 2025, and $12.1 million in Q2 2025.